Print

Studies for People With ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (VERITAC Studies)

https://www.facingourrisk.org/research-clinical-trials/study/269/studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-veritac-studies

Treatment
Treatment studies for ER-positive, HER2-negative metastatic breast cancer

Study Contact Information:

Pfizer Clinical Trial Contact Center by phone 1-800-887-7002 or email [email protected]

When calling the contact center, please reference the NCT number.


Researchers at Pfizer and Arvinas are conducting the VERITAC-2 and VERITAC-3 studies for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer. The studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant or PF-07850327), and how well it works either alone or combined with another breast cancer medicine, palbociclib (also known as IBRANCE®).

ARV-471 is believed to work by targeting and degrading the estrogen receptor that is found in breast cancer cells. This prevents estrogen from connecting to the cancer cells, which may block estrogen’s effect on cancer cell growth.

About the studies:

What the Studies Involve

Any additional screening, biopsies, appointments, monitoring

Any additional follow ups or steps involved in participation and a timeline

Any compensation they may receive for treatment-related costs

Study Locations

Visit these links for a full list of participating locations. 

Lead Researchers/Study PI's


This Study is Open To:

People with the following may be eligible: 

VERITAC-2:

*CDK4/6 inhibitors include medications called Ibrance, which is also called palbociclib, Kisqali, which is also called ribociclib, and Verzenio, which is also called abemaciclib.

VERITAC-3:

There are other requirements to join this study. The study doctor will help determine if this study is right for you.

This Study is Not Open To:

People with the following are not eligible: 

There are other requirements to join this study. The study doctor will help determine if this study is right for you.


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.